Cite
HARVARD Citation
Ellwanger, K. et al. (2015). EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors. Journal for immunotherapy of cancer. 3 (2), p. 1. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ellwanger, K. et al. (2015). EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors. Journal for immunotherapy of cancer. 3 (2), p. 1. [Online].